Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Ribon Therapeutics is raising $60,150,139.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Victoria Richon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ribon Therapeutics
Pioneering The Development of Novel Precision Oncology Drugs Targeting Stress Support Pathways. Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform. Within the emerging field of stress support pathway biology, we are focusing on a set of enzymes, including PARP7, that utilize nicotinamide adenine dinucleotide, or NAD+, a co-substrate that is central to cellular metabolism. NAD+ regulates functions such as DNA replication and gene transcription under conditions of cellular stress. We believe that this linkage between the intrinsic cellular stress response and the extrinsic activation of both the innate and adaptive immune systems is an attractive area for cancer drug development, since cancer cells have high levels of cellular stress and modulating the immune system can lead to antitumor activity.

To learn more about Ribon Therapeutics, visit http://ribontx.com/

Contact:
Victoria Richon, President and Chief Executive Officer
617-914-8700
vrichon@ribontx.com
https://www.linkedin.com/in/victoria-richon-b6abb2a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved